RxSight, Inc. (RXST)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$6.38-2.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · RXST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -45.9% |
| Our one-year growth estimate | diamond | 14.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 59.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
RXST — CEO transition
Dated 2026-07-15
President and Chief Executive Officer — Aziz Mottiwala: Aziz Mottiwala was appointed as President and Chief Executive Officer, replacing Ron Kurtz, M.D.
Why it matters: Successful launches of new products could drive future revenue growth and market share.
Supportive ifSuccessful launches or clinical trials for new lenses.
Worry ifDelays or problems in developing new products.
Why it matters: New leadership may bring fresh strategies that impact growth and market positioning.
Watch forLook for announcements about new plans or changes from CEO Aziz Mottiwala.
Also watch forNo new plans announced in the next quarter.
Why it matters: Operating costs affect profits. The company wants to keep these between $150 and $160 million for 2026.
Worry ifOperating costs were below $150 million for Q2 2026.
Less concerning ifOperating costs were above $160 million for Q2 2026.
Why it matters: Gross margin is a key measure of profitability. The company aims for 70% to 72% for 2026, which impacts overall financial health.
Watch forGross margin reported at 72% or higher for Q2 2026.
Also watch forGross margin reported below 70% for Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$292 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $628 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,494 loss on $10,000 · 64.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Higher expenses could show inefficiencies. This might hurt financial health.
Worry ifQ3 expenses were more than $40 million.
Less concerning ifExpenses stay below $40 million.
Why it matters: New CEO Aziz Mottiwala may give new revenue guidance. This could affect investor confidence.
Supportive ifA press release or earnings call where the new CEO provides Q3 revenue guidance.
Worry ifNo guidance is given. There may be delays in starting guidance again.
Why it matters: Maintaining gross margin above 70% is key for profitability. It shows RxSight's ability to control costs.
Supportive ifGross margin was over 72%. This shows strong cost management.
Worry ifGross margin was under 70%. This shows possible cost issues.
Why it matters: A big drop in product sales shows strong competition and low consumer confidence.
Worry ifQ3 product sales decline year over year worse than 15%.
Less concerning ifQ3 product sales decline year over year less than 15% or show growth.
Why it matters: Progress with Alcon could increase future revenue and support the current strategy.
Supportive ifWatch for news about key milestones or new products from the Alcon partnership.
Worry ifNo news or delays in the Alcon partnership milestones.
Why it matters: High operating costs may show bad cost management. This can hurt financial health.
Worry ifOperating costs in 2026 are expected to be more than $160 million.
Less concerning ifOperating costs are reported at or below $150 million to $160 million.
Why it matters: A drop in gross margin may show rising costs and pressure on profits.
Worry ifGross margin reported below 70% for 2026.
Less concerning ifGross margin reported within the 73% to 75% range.